Literature DB >> 19181586

Dual-phase 99mTc-MIBI parathyroid imaging reveals synchronous parathyroid adenoma and papillary thyroid carcinoma: a case report.

Ming-Che Chang1, Shih-Chuan Tsai, Wan-Yu Lin.   

Abstract

The possibility of a coincidental appearance of hyperparathyroidism and thyroid cancer is not often considered because of its low incidence. Here, we present a case of a 49-year-old woman with a parathyroid adenoma coexisting with two sites of papillary thyroid carcinoma. Dual-phase 99mTc-methoxyisobutylisonitrile (MIBI) parathyroid imaging before the operation correctly visualized the site of the parathyroid adenoma. In addition, two papillary thyroid carcinomas showed faint uptake of 99mTc-MIBI on delayed image. Total thyroidectomy and parathyroidectomy of a solitary parathyroid adenoma were performed. The patient subsequently underwent radioiodine-131 ablation and was treated with T4 suppression. This case illustrates the need for clinical awareness of concomitant hyperparathyroidism and thyroid cancer. Dual-phase 99mTc- MIBI parathyroid imaging may be useful for detecting indolent thyroid cancer before it becomes a distinct disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19181586     DOI: 10.1016/S1607-551X(09)70014-2

Source DB:  PubMed          Journal:  Kaohsiung J Med Sci        ISSN: 1607-551X            Impact factor:   2.744


  3 in total

1.  A Rare Constellation of Hürthle Cell Thyroid Carcinoma and Parathyroid Carcinoma.

Authors:  Mehrnoosh Zakerkish; Elham Rajaei; Mehrdad Dargahi; Mohammad Bahadoram
Journal:  J Clin Diagn Res       Date:  2015-12-01

2.  Diagnostic Value of Semiquantitative Analysis of 99mTechnetium-Methoxyisobutylisonitrile (99mTc-MIBI) Imaging in Predicting Early-Stage Cervical Lymph Node Metastasis of Thyroid Carcinoma.

Authors:  Xiao-Chun Zhu; Kai Zhou; Shi-Qing Xu; Yu-Bo Ma
Journal:  Med Sci Monit       Date:  2017-03-31

3.  A review of parathyroid mass and patients with nonspecific complaints.

Authors:  Aslıhan Dilara Demir
Journal:  J Int Med Res       Date:  2019-02-21       Impact factor: 1.671

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.